Use of botulinum toxin type A in poststroke spasticity

References

• Kurtzke JE The current neurologic burden of illness and injury in the united states. Neurology32(11), 1207–1214 (1982).
   Google Scholar
• Lance J. Pyramidal and extrapyramidal disorders. In:Electromyography in CNS Disorders. Shantani D (Ed.). Butterworth, Boston, MA, USA, 1–19, (1984).
   Google Scholar
• Mayer N. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motorneuron lesion. In: Spasticity: Etiology Evaluation, Management and the Role of Botulinum Toxin. Mayer N, Simpson DM (Eds). WeMove, New York, NY, USA, (2002).
   Google Scholar
• ••Recent review of treatment of spasticity with pharmacology of botulinum toxin described in easily understood diagrams.
   Google Scholar
• Terrence CF, Fromm GH, Roussan MS. Baclofen. Its effect on seizure frequency. Arch. Nemo'. 40(1), 28–29 (1983).
   Google Scholar
• Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology 44 (11) (Suppl. 9), S34—S42; discussion S33—S42 (1994).
   Google Scholar
• Holden KR, Titus MO. The effect of tiagabine on spasticity in children with intractable epilepsy: a pilot study. Pedlar. Neural 21(4), 728–730 (1999).
   PubMedGoogle Scholar
• Penn RD, Kroin JS. Continuous intrathecal baclofen for severe spasticity. Lancet2(8447), 125–127 (1985).
   PubMedGoogle Scholar
• Meinck HM, Tronnier V, Rieke K, Wirtz CR, Flugel D, Schwab S. Intrathecal baclofen treatment for stiff-man syndrome: pump failure may be fatal. Neurology 44 (11), 2209–2210 (1994).
   PubMedGoogle Scholar
• Scott AB, Kraft SR Botulinum toxin injection in the management of lateral rectus paresis. Ophthalmology92(5), 676–683 (1985).
   PubMedGoogle Scholar
• Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology 41(7), 1088–1091 (1991).
   PubMed Web of Science ®Google Scholar
• Brin, MF, Aoki KR. Botulinum tobal type A: pharmacology. In: Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin. Mayer N, Simpson DM (Eds). WeMove, New York, NY, USA, (2002).
   Google Scholar
• Brashear A, Gordon ME, Elovic E et al Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Eng/. I Med. 347(6), 395–400 (2002).
   Google Scholar
• ••Most recent publication on the use ofbotulinum toxin type A (BOTOX®), for poststroke spasticity. Discusses results of a Phase III pivotal trial.
   Google Scholar
• Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double-blind placebo-controlled trial. Neural Neurosurg. P4chiatry69(2), 217–221 (2000).
   Google Scholar
• Brashear A, Zafonte R, Corcoran M et al. Inter- and intrarater reliability of the Ashworth scale and the disability assessment scale in patients with upper limb poststroke spasticity. Arch. Phys. Med. Rehabil 83(10), 1349–1354 (2002).
   Google Scholar
• •Recent publication on the reliability of the Ashworth scale and the new, novel Disability Assessment Scales (DAS). The DAS was designed specifically to assess changes in functional disability after treatment with botulinum toxin type A.
   Google Scholar
• Childers MK, Brashear A, Jozefczyk PB et al A multicenter, double-blind, placebo-controlled dose response trial of botulinum toxin type A (Botox) in upper limb spasticity post-stroke (abstract). Neurology 52(6), A295 (1999).
   Google Scholar
• Simpson DM, Alexander DN, O'Brien CF et al Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 46 (5), 1306–1310 (1996).
   PubMed Web of Science ®Google Scholar
• •Results of a dose finding trial of botulinum toxin type A (BOTOX®), in poststroke spasticity.
   Google Scholar
• Bakheit AM, Thilmann AF, VVard AB etal A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 31 (10), 2402–2406 (2000).
   PubMed Web of Science ®Google Scholar
• Brashear A, Kuhn ER, McAfee A, Fyffe J. Double-blind, placebo-controlled trial of botulinum toxin type B in upper limb spasticity. Neumlogy60 (1) A30 (2003) (Abstract).
   Google Scholar
• Lagalla, G, Danni M, Reiter F, Ceravolo MG, Provinciali L. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am. Phys. Merl Rehabil 79(4), 377–384; quiz 391–374 (2000).
   Google Scholar
• •The only repeated use study of botulinum toxin type A (BOTOXe) in poststroke spasticity.
   Google Scholar
• Gordon MFBA, Elovic E, Kassicieh D etal A multicenter, open-label, study of the safety and efficacy of repeated botulinum toxin type A doses in post-stroke, focal, upper limb spasticity (abstract). Neurology 58 (Suppl. 3), A221 (2002).
   Google Scholar
• Brashear A, McAfee AL, Kuhn ER, Ambrosius WT Treatment with botulinum toxin type B for upper limb spasticity. Arch. Phys. Merl Rehabil 84(1), 103–107 (2003).
   Google Scholar
• ••First reported use of botulinum toxin type B (MycoBlocTm) in upper extremity spasticity. Side effects of dry mouth were common.
   Google Scholar